BamSEC and AlphaSense Join Forces
Learn More

SELLAS Life Sciences Group Inc. – Material Contracts

NASDAQ: SLS    
Share price (3/25/26): $5.30    
Market cap (3/25/26): $952 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 9 pages Material contract
12/34/56
EX-10.1
from 8-K 2 pages October 1, 2025 SELLAS Life Sciences Group, Inc. 7 Times Square, 25th Floor, New York Ny 10036 Re: Time Square Tower, 7 Time Square, New York, Ny (The “Building”) Ladies and Gentlemen
12/34/56
EX-10.1
from 8-K 13 pages Material contract
12/34/56
EX-10.1
from 10-Q 8 pages SELLAS Life Sciences Group, Inc. Amended and Restated Employee Stock Purchase Plan Amended and Restated on June 17, 2025
12/34/56
EX-10.13
from 10-K 2 pages February __, 2025 Personal and Confidential Re: Amendment to Change in Control Severance Agreement
12/34/56
EX-10.12
from 10-K 2 pages February __, 2025 Personal and Confidential Re: Amendment to Change in Control Severance Agreement
12/34/56
EX-10.11
from 10-K 7 pages January 22, 2024 1. Severance
12/34/56
EX-10.9
from 10-K 3 pages Employment: You Will Be Employed on a Full-Time Basis as Senior Vice President, Clinical Research & Development, in Our New York Office, Commencing on February 3, 2020. You Will Report to the Company’s Chief Executive Officer (The “CEO”) and Have the Duties and Responsibilities That Are Consistent With Your Position and Such Other Duties as May From Time to Time Be Assigned to You by the Company
12/34/56
EX-10.1
from 8-K 29 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 2 pages October 2, 2024 SELLAS Life Sciences Group, Inc. 7 Times Square, 25th Floor, New York Ny 10036 Re: Time Square Tower, 7 Time Square, New York, Ny (The “Building”) Ladies and Gentlemen
12/34/56
EX-10.1
from 8-K 29 pages Securities Purchase Agreement
12/34/56
EX-10.51
from 10-K 15 pages Separation Agreement and General Release
12/34/56
EX-10.50
from 10-K 15 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because SELLAS Life Sciences Group, Inc. Has Determined the Information (I) Is Not Material and (II) the Company Customarily Treats That Information as Private. Date Provided to Employee: March 8, 2024 Confidential Separation Agreement and General Release
12/34/56
EX-10.49
from 10-K 3 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because SELLAS Life Sciences Group, Inc. Has Determined the Information (I) Is Not Material and (II) the Company Customarily Treats That Information as Private. February 25, 2022
12/34/56
EX-10.1
from 8-K 39 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 44 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 6 pages Second Amendment to Sublease
12/34/56
EX-10.1
from 8-K 37 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 10-Q 5 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because SELLAS Life Sciences Group, Inc. Has Determined the Information (I) Is Not Material and (II) Would Likely Cause Competitive Harm to SELLAS Life Sciences Group, Inc. if Publicly Disclosed Addendum to the Side Letter Agreement Between 3d Medicines Inc. and SELLAS Life Sciences Group, Inc
12/34/56
EX-10.1
from 10-Q 20 pages SELLAS Life Sciences Group, Inc. 2023 Amended and Restated Equity Incentive Plan Amended and Restated on June 20, 2023
12/34/56